3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
 
MMTC15_Header  
MMTC M Header 
2014 Archived Content

Cambridge Healthtech Institute’s Second Annual

Companion Diagnostics

Implementing the New Standard

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA  

Companion diagnostics are a key component of personalized medicine. The current environment will be reviewed and analyzed with regard to reimbursement and regulation of companion diagnostics, and recent approvals will be examined by key players in the industry. Opportunities that apply companion diagnostic drugs to improve patient care will be identified. Furthermore, the steps for implementing clinical decision support will be outlined.

Day 1 | Day 2 | Day 3Download Brochure 

Monday, February 10 

10:30 am Conference Program Registration 

11:50 Chairperson's Opening Remarks 

Julien N. Bradley, MBA, Senior Director, Sales & Marketing, Quanterix Corporation


12:00 pm KEYNOTE PANEL DISCUSSION:

CPT Coding

Moderator: Jill Hagenkord, M.D., CMO & Senior Vice President, InVitae

Elaine Lyon, Ph.D., Medical Director, Molecular Genetics, ARUP (2014 AMP President and 2013 AMP Economic Affairs, Professional Relations, Strategic Opportunities Committees)

Chris L. Jagmin, M.D., Senior Medical Director, National Medical Policy and Operations, Aetna

  • Overview of CPT codes
  • Transitioning to the molecular pathology codes from the clinical laboratory’s perspective
  • Understanding rationale behind new CPT codes
 

1:00 Session Break 

1:15 Luncheon Presentation I: Simoa HD-1: A Fully Automated, Multiplexed Immunoanalyzer with Single Molecule Sensitivity 

David C. Duffy, Ph.D., CTO, Quanterix Corporation

Single Molecule Array (Simoa) technology allows multiple proteins to be detected at concentrations 1000-fold lower than currently possible. Simoa is based on the capture of single molecules on paramagnetic beads, and their detection in arrays of femtoliter wells. We will illustrate the power of this analytical sensitivity in diagnosing cancer, neurological diseases, and infectious diseases using the Simoa HD-1 Analyzer, a fully automated instrument designed for use in clinical research and diagnosis.

1:45 Luncheon Presentation II: A Novel Exosome RNA Extraction Platform Enabling Biomarker Discovery and Diagnostic Development for Personalized Medicine

Johan Skog, Ph.D., CSO, Exosome Diagnostics

Exosomes are released by cells as an active process of communication, and contain stable, intact nucleic acids, making them an ideal source for biomarker discovery and diagnostic development. ExoRNeasy was optimized to extract RNA, including mRNA, microRNAs, and other RNAs, from plasma and serum. The high quality RNA generated from the ExoRNeasy kit enables profiling of tumor associated mutations as well as RNA levels in biofluids of cancer patients.

2:15 Session Break 

Co-Organized with
PMC
 

2:30 PANEL DISCUSSION: Opportunities and Challenges in Commercializing Esoteric Diagnostics 

Moderator: Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Organized by the Personalized Medicine Coalition, this panel will outline both the promise and the pitfalls in bringing new molecular diagnostics to market, including the scientific, regulatory, payment, and adoption issues that innovative diagnostics companies must negotiate. Featuring leaders in the field, it will provide insight into best practices and likely scenarios for future trends.

Laura Brege, MBA, CEO, Nodality, Inc.

Peter Maag, Ph.D., CEO, XDx, Inc.

Jay Wohlgemuth, M.D., Senior Vice President, Science  & Innovation, Quest Diagnostics

Alan Wright, M.D., MPH, CMO, Roche Diagnostics

3:45 Next-Gen Sequencing for Prostate Cancer 

Philip D. Cotter, Ph.D., FACMG, FFSc(RCPA), Principal, ResearchDx

Diagnostic and prognostic assessment of prostate cancer has been dramatically improved by the use of new laboratory technologies. This presentation focuses on the use of gene panel and pathway analyses using Next-Gen sequencing approaches in prostate cancer.

4:00 Models for the Development of Multiplex Companion Diagnostics 

Austin Tanney, Ph.D., Scientific Liaison Manager, Almac


4:15 A Bioinformatics Framework for Clinical Research Sequencing  

Daniel Rhodes, Ph.D., Head, Medical Science Informatics, Life Technologies

The widespread adoption of precision medicine in oncology requires: a compendium of therapies targeting the genetic vulnerabilities of cancer; the diagnostic tools capable of generating a precise molecular diagnosis; and importantly, the information systems to connect a patient’s molecular diagnosis to optimal treatment hypotheses. Here, we will present Life Technologies’ work to accelerate (1) defining the landscape of actionable driver genetic events in cancer, (2) developing a next-generation sequencing screen on the Ion Torrent semiconductor-sequencing platform, (3) assembling treatment-related information relevant for clinical research, and (4) devising a turnkey bioinformatics solution to democratize clinical sequencing in the future.

4:30 Refreshment Break and Transition to Plenary Keynote 

 

5:00 Plenary Keynote Session (Click Here For More Details)  


6:15 Grand Opening Reception in the Exhibit Hall with Poster Viewing 

7:45 Close of Day 



Day 1 | Day 2 | Day 3Download Brochure 

 


  2015 Plenary Sessions 


2015 MMTC Prelim Agenda 

Premier Sponsors:

 

Elsevier 


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Singulex